Bp Plc grew its holdings in Becton Dickinson and Co (NYSE:BDX) by 74.1% during the second quarter, HoldingsChannel.com reports. The firm owned 74,000 shares of the medical instruments supplier’s stock after acquiring an additional 31,500 shares during the quarter. Bp Plc’s holdings in Becton Dickinson and were worth $17,739,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. BDO Wealth Advisors LLC grew its position in shares of Becton Dickinson and by 361.6% during the 1st quarter. BDO Wealth Advisors LLC now owns 577 shares of the medical instruments supplier’s stock worth $125,000 after buying an additional 452 shares in the last quarter. Kaizen Advisory LLC grew its position in shares of Becton Dickinson and by 155.9% during the 2nd quarter. Kaizen Advisory LLC now owns 609 shares of the medical instruments supplier’s stock worth $146,000 after buying an additional 371 shares in the last quarter. Karp Capital Management Corp bought a new position in shares of Becton Dickinson and during the 1st quarter worth $177,000. Clarus Wealth Advisors bought a new position in shares of Becton Dickinson and during the 2nd quarter worth $188,000. Finally, Affinity Investment Advisors LLC bought a new position in shares of Becton Dickinson and during the 1st quarter worth $202,000. Institutional investors and hedge funds own 84.16% of the company’s stock.
In related news, Director David F. Melcher acquired 500 shares of the company’s stock in a transaction that occurred on Monday, May 7th. The shares were bought at an average price of $225.07 per share, with a total value of $112,535.00. Following the completion of the transaction, the director now directly owns 2,728 shares in the company, valued at $613,990.96. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alexandre Conroy sold 20,128 shares of the firm’s stock in a transaction dated Monday, May 21st. The shares were sold at an average price of $228.74, for a total value of $4,604,078.72. Following the sale, the insider now directly owns 35,583 shares in the company, valued at approximately $8,139,255.42. The disclosure for this sale can be found here. 1.00% of the stock is owned by company insiders.
A number of equities analysts have recently issued reports on BDX shares. ValuEngine raised Becton Dickinson and from a “hold” rating to a “buy” rating in a research report on Wednesday, April 18th. Citigroup raised Becton Dickinson and from a “neutral” rating to a “buy” rating and increased their price target for the stock from $237.00 to $251.00 in a research report on Tuesday, April 10th. Finally, JPMorgan Chase & Co. raised Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price target on the stock in a research report on Thursday, June 21st. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $240.88.
BDX stock traded down $2.98 during trading on Monday, reaching $247.22. 69,302 shares of the company traded hands, compared to its average volume of 757,232. Becton Dickinson and Co has a 12 month low of $191.53 and a 12 month high of $252.74. The company has a market cap of $66.85 billion, a P/E ratio of 26.39, a PEG ratio of 1.74 and a beta of 1.12. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.70 and a quick ratio of 1.12.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 3rd. The medical instruments supplier reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.63 by $0.02. Becton Dickinson and had a positive return on equity of 14.27% and a negative net margin of 0.46%. The company had revenue of $4.22 billion for the quarter, compared to the consensus estimate of $4.12 billion. During the same quarter last year, the company earned $2.30 earnings per share. The firm’s revenue for the quarter was up 42.2% compared to the same quarter last year. analysts anticipate that Becton Dickinson and Co will post 10.99 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 28th. Investors of record on Friday, September 7th will be given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 1.21%. The ex-dividend date is Thursday, September 6th. Becton Dickinson and’s payout ratio is currently 31.65%.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Recommended Story: Closed-End Mutual Funds (CEFs)
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.